Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone

被引：1
作者：
Wong, Jacky [1 ]
Welschinger, Robert [1 ]
Baraz, Rana [1 ]
Bradstock, Kenneth Francis [2 ]
Bendall, Linda J. [3 ]
机构：
[1] Westmead Millenium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
[2] Westmead Hosp, Westmead, NSW 2145, Australia
[3] Westmead Millennium Inst, Westmead, NSW, Australia
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3575.3575
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1526 / 1526
页数：1
相关论文
共 50 条
  • [31] Mechanisms of resistance to dual PI3K-mTOR inhibition in NSCLC cell lines
    Heavey, S.
    Dowling, P.
    Barr, M.
    Cuffe, S.
    Finn, S.
    O'Byrne, K. J.
    Gately, K. A.
    LUNG CANCER, 2015, 87 : S2 - S2
  • [32] Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition
    Lee, Misu
    Theodoropoulou, Marily
    Graw, Jochen
    Roncaroli, Federico
    Zatelli, Maria Chiara
    Pellegata, Natalia S.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (08) : 1450 - 1459
  • [33] Comparative Use of Single mTOR vs Dual mTOR/PI3K Inhibition in Regulatory T Cell Expansion for Clinical Application in Transplantation.
    Gedaly-Eidelman, R.
    Marti, F.
    Turcios, L.
    Chacon, E.
    Valvi, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 1050 - 1051
  • [34] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Serova, Maria
    de Gramont, Armand
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Riveiro, Maria Eugenia
    Slimane, Khemaies
    Faivre, Sandrine
    Raymond, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1297 - 1307
  • [35] Dual Inhibition of PI3Kα and mTOR as an Alternative Treatment for Kaposi's Sarcoma
    Chaisuparat, Risa
    Hu, Jiadi
    Jham, Bruno C.
    Knight, Zachary A.
    Shokat, Kevan M.
    Montaner, Silvia
    CANCER RESEARCH, 2008, 68 (20) : 8361 - 8368
  • [36] SYNERGY OF VENETOCLAX AND DUAL MTOR/PI3K INHIBITION IN BCP-ALL
    Niedermayer, Alexandra
    Enzenmueller, Stefanie
    Seyfried, Felix
    Debatin, Klaus-Michael
    Meyer, Lüder
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [37] Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
    Qian, Xiao-jun
    Li, Yun-tian
    Yu, Yan
    Yang, Fen
    Deng, Rong
    Ji, Jiao
    Jiao, Lin
    Li, Xuan
    Wu, Rui-Yan
    Chen, Wen-Dan
    Feng, Gong-Kan
    Zhu, Xiao-Feng
    ONCOTARGET, 2015, 6 (07) : 5134 - 5146
  • [38] Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
    Venkatesan, Aranapakam M.
    Dehnhardt, Christoph M.
    Chen, Zecheng
    Delos Santos, Efren
    Dos Santos, Osvaldo
    Bursavich, Matthew
    Gilbert, Adam M.
    Ellingboe, John W.
    Ayral-Kaloustian, Semiramis
    Khafizova, Gulnaz
    Brooijmans, Natasja
    Mallon, Robert
    Hollander, Irwin
    Feldberg, Larry
    Lucas, Judy
    Yu, Ker
    Gibbons, Jay
    Abraham, Robert
    Mansour, Tarek S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (02) : 653 - 656
  • [39] DUAL INHIBITION OF THE MTOR AND PI-3K PATHWAYS INDUCES ANTI-PROLIFERATIVE EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND PROLONGS SURVIVAL IN VIVO
    Wong, S. K.
    Welschinger, R.
    Baraz, R.
    Bradstock, K.
    Bendall, L. J.
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S43 - S43
  • [40] Novel imidazolopyrimidines as dual PI3-kinase/mTor inhibitors
    Dehnhardt, Christoph
    Venkatesan, Aranapakam
    Chen, Zecheng
    Delos Santos, Efren
    Santos, Oswaldo
    Bursavich, Matthew
    Brooijmans, Natasja
    Mallon, Robert
    Hollander, Irwin
    Feldberg, Larry
    Lucas, Judy
    Yu, Ker
    Ayral-Kaloustian, Semiramis
    Gibbons, Jay
    Abraham, Robert
    Mansour, Tarek
    CANCER RESEARCH, 2009, 69
12345